Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-22 08:27 am Sale |
2025-03-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
BlackRock Inc. BLK |
8,197,023 14.700% |
-2,184,295 (-21.04%) |
Filing History |
| 2025-02-14 5:20 pm Sale |
2024-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
Armistice Capital, LLC | 4,836,000 8.760% |
-260,000 (-5.10%) |
Filing History |
| 2024-11-14 5:14 pm Purchase |
2024-09-30 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
Armistice Capital, LLC | 5,096,000 9.250% |
446,000 (+9.59%) |
Filing History |
| 2024-11-01 4:35 pm Sale |
2024-09-30 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
Macquarie Group Limited | 2,631,897 4.780% |
-105,824 (-3.87%) |
Filing History |
| 2024-10-31 11:55 am Purchase |
2024-10-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
Dimensional Fund Advisors LP | 2,882,505 5.200% |
2,882,505 (New Position) |
Filing History |
| 2024-02-14 2:33 pm Purchase |
2023-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
Armistice Capital, LLC | 4,650,000 8.510% |
294,000 (+6.75%) |
Filing History |
| 2024-02-14 07:06 am Purchase |
2023-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
Macquarie Group Limited | 2,737,721 5.010% |
2,737,721 (New Position) |
Filing History |
| 2024-02-13 5:15 pm Purchase |
2023-12-29 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
The Vanguard Group | 6,214,731 11.380% |
424,771 (+7.34%) |
Filing History |
| 2024-01-19 2:40 pm Purchase |
2023-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
BlackRock Inc. BLK |
10,381,318 19.000% |
777,245 (+8.09%) |
Filing History |
| 2023-02-14 1:33 pm Purchase |
2022-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
Armistice Capital, LLC | 4,356,000 8.060% |
220,000 (+5.32%) |
Filing History |
| 2023-02-09 11:32 am Purchase |
2022-12-30 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
The Vanguard Group | 5,789,960 10.710% |
276,811 (+5.02%) |
Filing History |
| 2023-01-23 3:52 pm Purchase |
2022-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
BlackRock Inc. BLK |
9,604,073 17.800% |
1,153,051 (+13.64%) |
Filing History |
| 2022-02-14 7:03 pm Purchase |
2021-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
Armistice Capital, LLC | 4,136,000 7.800% |
1,016,000 (+32.56%) |
Filing History |
| 2022-02-10 08:37 am Purchase |
2021-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
The Vanguard Group | 5,513,149 10.370% |
215,071 (+4.06%) |
Filing History |
| 2022-01-27 5:14 pm Unchanged |
2021-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
BlackRock Inc. BLK |
8,451,022 15.900% |
0 (Unchanged) |
Filing History |
| 2022-01-26 09:16 am Sale |
2021-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
BlackRock Inc. BLK |
8,451,022 15.900% |
-461,779 (-5.18%) |
Filing History |
| 2021-02-16 5:00 pm Purchase |
2020-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
Armistice Capital, LLC | 3,120,000 5.900% |
232,000 (+8.03%) |
Filing History |
| 2021-02-10 11:57 am Sale |
2020-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
The Vanguard Group | 5,298,078 10.060% |
-7,811 (-0.15%) |
Filing History |
| 2021-01-25 4:50 pm Purchase |
2020-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN |
BlackRock Inc. BLK |
8,912,801 16.900% |
177,969 (+2.04%) |
Filing History |